Off-Label Use of Bumetanide for Brain Disorders: An Overview
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Bumetanide (BTN or BUM) is an FDA-approved potent loop diuretic (LD) that acts by antagonizing NKCC1/NKCC2, a sodium-potassium-chloride (Na-K-Cl) cotransporter which is expressed both in the CNS and in systemic organs. The off-label use of BTN to modulate neuronal transmembrane Cl- gradients by blocking NKCC1 in the CNS has now been tested as an anti-seizure agent and as an intervention for neurological disorders in pre-clinical studies with varying results. BTN safety and efficacy for its off-label use has also been tested in several clinical trials for neonates, children, adolescents and adults. It failed to meet efficacy criteria for hypoxic-ischemic encephalopathy (HIE) neonatal seizures. In contrast, positive outcomes in temporal lobe epilepsy (TLE), autism, and schizophrenia trials have been attributed to BTN in studies evaluating its off-label use. NKCC1 is a electroneutral neuronal Cl- importer and the dominance of NKCC1 function has been proposed as the common pathology for HIE seizures, TLE, autism, and schizophrenia. Therefore, the use of BTN to antagonize neuronal NKCC1 with the goal to lower internal Cl- levels and promote GABAergic mediated hyperpolarization has been proposed. In this review, we summarize the data and results for pre-clinical and clinical studies that have tested off-label BTN interventions and report variable outcomes. We also compare the data underlying the developmental expression profile of NKCC1 and KCC2, highlight the limitations of BTN’s brain-availability and consider its actions on non-neuronal cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
The K+/Cl− co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation
Rivera, C., Voipio, J., Payne, J. A., Ruusuvuori, E., Lahtinen, H., Lamsa, K., Pirvola, U., Saarma, M., & Kaila, K. (1999) · Nature · doi:10.1038/16697 · Cited by 2,152 · cited 2×
“However, the developmentally regulated low expression and function of KCC2 at birth may also play a significant role in determining Cl− gradients during early postnatal weeks (Rivera et al., 1999; Lee et al., 2005).”
BackgroundSize-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Physiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766 · cited 1×
“The relationship between aquaporin 4 (AQP4) and NKCC1 has been investigated in the CNS; AQP4 effluxes water in response to NKCC1 transporting water (Østby et al., 2009; Zeuthen, 2010; Nagelhus and Ottersen, 2013), indicating other possible sites for BTN mediated modulation.”
BackgroundOxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
Tyzio, R., Nardou, R., Ferrari, D. C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G., et al. (2014) · Science · doi:10.1126/science.1247190 · Cited by 601 · cited 1×
“Based on these hypotheses, reducing the [Cl]i via BTN proved efficacious in an animal model of autism using valproic acid exposure (Tyzio et al., 2014).”
Yamada, J., Okabe, A., Toyoda, H., Kilb, W., Luhmann, H. J., & Fukuda, A. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.062471 · Cited by 572 · cited 3×
“The developmental expression profile of NKCC1 mRNA has been examined in postmortem human brains with RT-PCR and was found to be stable postnatally (Morita et al., 2014).”
MethodA randomised controlled trial of bumetanide in the treatment of autism in children
Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., Hadjikhani, N., & Ben-Ari, Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.124 · Cited by 322
Schizophrenia and the frontal lobe
WEINBERGER, D. (1988) · Trends in Neurosciences · doi:10.1016/0166-2236(88)90060-4 · Cited by 262
Lemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., Brosset, P., Viellard, M., Bernoux, D., Rondeau, S., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.10 · Cited by 218 · cited 1×
“In three separate clinical trials where BTN was administered to patients with autism ranging from infancy to adulthood, BTN significantly improved Childhood Autistic Rating Scale (CARS) scores and attenuated the severity of the disorder overall, with no major side effects other than diuresis (Lemonnier and BenAri, 201…”
BackgroundSu, G., Kintner, D. B., Flagella, M., Shull, G. E., & Sun, D. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00538.2001 · Cited by 169 · cited 1×
“In the CNS, NKCC1 is also expressed in ependymal and glial cells (Plotkin et al., 1997a; Wu et al., 1998; Hubner et al., 2001; Kanaka et al., 2001; Yan et al., 2001a,b; Mikawa et al., 2002; Su et al., 2002; Wang et al., 2003; Sun, 2010).”
Background
Cited by
Taubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
Sprengers, J. J., van Andel, D. M., Zuithoff, N. P. A., Keijzer-Veen, M. G., Schulp, A. J. A., Scheepers, F. E., Lilien, M. R., Oranje, B., & Bruining, H. (2021) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.07.888 · Cited by 97
Juarez-Martinez, E. L., Sprengers, J. J., Cristian, G., Oranje, B., van Andel, D. M., Avramiea, A.-E., Simpraga, S., Houtman, S. J., Hardstone, R., Gerver, C., et al. (2023) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.08.009 · Cited by 48
Bumetanide for autism: open-label trial in six children
Fernell, E., Gustafsson, P., & Gillberg, C. (2021) · Acta Paediatrica · doi:10.1111/apa.15723 · Cited by 34
Metadata
- Authors
- Kharod, S. C., Kang, S. K., & Kadam, S. D.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-04-24
- Volume
- 13
- Pages
- 310-310
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2941139684
- Cited by
- 107
- References
- 15
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Off-Label Use of Bumetanide for Brain Disorders: An Overview. https://app.cochat.ai/papers/10.3389/fnins.2019.00310
- The paper
- Kharod, S. C., Kang, S. K., & Kadam, S. D. (2019). Off-Label Use of Bumetanide for Brain Disorders: An Overview. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2019.00310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.